| 1 |
陈艳丽，王媛媛，张 勇，等. 中晚期非小细胞肺癌患者化疗前后T淋巴细胞亚群表达差异分析及临床意义[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(1): 13-17.
|
| 2 |
Fujino T, Suda K, Mitsudomi T. Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer[J]. Expert Opin Emerg Dr, 2020, 25(3): 229-249.
|
| 3 |
Li WQ, Cui JW. Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments[J]. J Cancer Res Clin Oncol, 2020, 146(9): 2329-2338.
|
| 4 |
Salgia R, Sattler M, Scheele J, et al. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping[J]. Cancer Treat Rev, 2020, 87(69): 102022-102038.
|
| 5 |
Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(2): 198-211.
|
| 6 |
Theelen WSME, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials[J]. Lancet Res Med, 2021, 9(5): 467-475.
|
| 7 |
Redman MW, Papadimitrakopoulou VA, Minichiello K, et al. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol[J]. Lancet Oncol, 2020, 21(12): 1589-1601.
|
| 8 |
徐 瑜，白 莉. 广泛期小细胞肺癌免疫治疗新理念[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 407-411.
|
| 9 |
Zhang Q, Rong Y, Yi K, et al. Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications[J]. Theranostics, 2020, 10(26): 12060-12071.
|
| 10 |
Yu J, Gemenetzis G, Kinny-Köster B, et al. Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing[J]. Cancer Lett, 2020, 493(696): 245-253.
|
| 11 |
Donato C, Kunz L, Castro-Giner F, et al. Hypoxia triggers the intravasation of clustered circulating tumor cells[J]. Cell Rep, 2020, 32(10): 108105-108112.
|
| 12 |
Pearsall SM, Humphrey S, Revill M, et al. The rare YAP1 subtype of SCLC revisited in a biobank of 39 circulating tumor cell patient derived explant models: A brief report[J]. J Thorac Oncol, 2020, 15(12): 1836-1843.
|
| 13 |
刘光艺，黄 镇，王子卫. 第8版国际抗癌联盟和美国癌症联合委员会胃癌TNM分期系统简介及解读[J]. 腹部外科，2017, 30(4): 241-245.
|
| 14 |
Pei X, Chen SW, Long X, et al. circMET promotes NSCLC cell proliferation, metastasis, and immune evasion by regulating the miR-145-5p/CXCL3 axis[J]. Aging (Albany NY), 2020, 12(13)：13038-13058.
|
| 15 |
Urbanska EM, Sørensen JB, Santoni-Rugiu E. Treatment algorithm for advanced ALK-rearranged NSCLC[J]. J Thorac Oncol, 2020, 15(9): e156-e157.
|
| 16 |
Cheng R, Lu X, Xu C, et al. SNHG11 contributes to NSCLC cell growth and migration by targeting miR-485-5p/BSG axis[J]. Biomed Pharmacother, 2020, 128(119): 110324-110327.
|
| 17 |
Pham D, Bhandari S, Pinkston C, et al. NSCLC patient "migration" for treatment: A retrospective analysis of patient characteristics, travel patterns, and survival differences[J]. Curr Probl Cancer, 2020, 4(4): 100528-100533.
|
| 18 |
陈 燏，王玉秀，闵凌峰. NIX蛋白表达与非小细胞肺癌临床病理特征及预后[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 412-416.
|
| 19 |
任艳苓，高 鹏. 肺癌患者化疗治疗前后CT影像学疗效评估[J]. 中外女性健康研究，2019, 69(9): 32-33.
|
| 20 |
丛 悦，范智慧，戴 莹，等. 应用剪切波弹性成像技术评价局部进展期直肠癌新辅助放化疗后病灶的初步经验[J]. 中华超声影像学杂志，2019, 28(10): 901-906.
|
| 21 |
伦俊杰，孙建业，胡效坤，等. 肝癌TACE术后残存病灶的判断方法及125I放射粒子治疗后疗效检测[J]. 医学影像学杂志，2014, 123(12): 2125-2128.
|
| 22 |
俞尹华. 探索分析针对广泛期肺癌化疗患者实施护理干预的方法及对病人生活质量的影响效果[J]. 健康必读，2020, 10(12): 135-136.
|
| 23 |
Rossi T, Gallerani G, Angeli D, et al. Single-cell NGS-based analysis of copy number alterations reveals new insights in circulating tumor cells persistence in early-stage breast cancer[J]. Cancers (Basel), 2020, 12(9): 2490-2497.
|
| 24 |
Sawabata N, Nakamura T, Kawaguchi T, et al. Circulating tumor cells detected only after surgery for non-small cell lung cancer: is it a predictor of recurrence？[J]. J Thorac Dis, 2020, 12(9): 4623-4632.
|
| 25 |
Liu WR, Zhang B, Chen C, et al. Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non-small cell lung cancer[J]. Thorac Cancer, 2020, 11(11): 3234-3242.
|
| 26 |
Liberko M, Kolostova K, Szabo A, et al. Circulating tumor cells, circulating tumor DNA and other blood-based prognostic scores in pancreatic ductal adenocarcinoma-mini-review[J]. In Vivo, 2021, 35(1): 31-39.
|
| 27 |
Lee JH, Eberhardt M, Blume K, et al. Evidence for liver and peripheral immune cells secreting tumor-suppressive extracellular vesicles in melanoma patients[J]. E Bio Med, 2020, 62(77): 103119-103125.
|
| 28 |
张孝钦，陈玄一，邬盛昌. 循环肿瘤细胞在晚期非小细胞肺癌化疗疗效监测及预后预测中的价值研究[J]. 中国全科医学，2020, 23(2): 183-188.
|
| 29 |
刘丽娜，尹先哲，李毅星，等. 外周血CTC阴性富集联合FISH在监测转移性乳腺癌中的应用及临床价值[J]. 医药与保健，2019, 27(10): 159-160.
|
| 30 |
Tian D, Zhang M, Zheng G, et al. Clinical significance of phenotyping and karyotyping of detecting circulating tumor cells in renal cell carcinoma using subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH)[J]. Int Urol Nephrol, 2020, 52(12): 2281-2287.
|